Cosmos Health Secures 253,657-Unit Manufacturing Orders for Broad Medicine Range
COSM•Cosmos Health's Cana Laboratories secured new manufacturing orders totaling 253,657 units for Gritse oral solutions, Fungofort spray, Paco-4 tablets, dexamethasone oral solutions and Foproct rectal cream. Orders from Nassington and Verisfield expand the company’s contract manufacturing pipeline and support revenue growth in its vertically integrated pharmaceutical platform.
1. Order Details
Cosmos Health’s subsidiary Cana Laboratories received combined orders of 253,657 units from Nassington and Verisfield, covering oral solutions, sprays, tablets and creams.
2. Product Breakdown
The scope includes Gritse oral solution at 0.4 mg/ml (150 ml) and 2 mg/ml and 4 mg/ml Forte formulations (50 ml), Fungofort cutaneous spray (30 ml), Paco-4 tablets (250+250+65+35 mg), dexamethasone oral solutions in 50 ml and 150 ml, and Foproct rectal cream (1 + 1.5%).
3. Manufacturing Capabilities
Cana operates under European GMP certification and EMA approval, offering a vertically integrated platform capable of producing pharmaceuticals, nutraceuticals and medical devices across multiple dosage forms, supporting quality compliance and scalability.
4. Strategic Implications
These contracts strengthen Cosmos Health’s manufacturing pipeline, diversify revenue streams and reinforce partnerships with established pharmaceutical companies, underpinning the company’s long-term value creation and capacity expansion in contract manufacturing.
